ReviewSeminars in immunopathology2014
Impacts of the apoptosis inhibitor of macrophage (AIM) on obesity-associated inflammatory diseases.
Review in Seminars in immunopathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 34 citations in OpenAlex.
- Apoptosis Inhibitor of Macrophage (AIM) Modulates Calcium Oxalate-Induced Ureteral Fibrosis in AIM-Felinized Mice.International journal of molecular sciences · 2025Article
- Cryo-EM reveals structural basis for human AIM/CD5L recognition of polymeric immunoglobulin M.Nature communications · 2024Article
- Administration of an antibody against apoptosis inhibitor of macrophage prevents aortic aneurysm progression in mice.Scientific reports · 2024Article
- The effects of apoptosis inhibitor of macrophage in kidney diseases.European journal of medical research · 2024Review
- Absolute Quantification of Pan-Cancer Plasma Proteomes Reveals Unique Signature in Multiple Myeloma.Cancers · 2023Article
- Role of apoptosis inhibitor of macrophages in patients with IgG4‑related disease/autoimmune pancreatitis and the clinical characteristics associated with this condition.Biomedical reports · 2022Article
- The Roles of Adipose Tissue Macrophages in Human Disease.Frontiers in immunology · 2022Review
- Apoptosis inhibitor of macrophage as a biomarker for disease activity in Japanese children with IgA nephropathy and Henoch-Schönlein purpura nephritis.Pediatric research · 2021Article
- Does Proteomic Mirror Reflect Clinical Characteristics of Obesity?Journal of personalized medicine · 2021Article
- Association between apoptosis inhibitor of macrophage and microsatellite instability status in colorectal cancer.BMC gastroenterology · 2020Article
- Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.Diagnostics (Basel, Switzerland) · 2020Review
- AIM-deficient mouse fed a high-trans fat, high-cholesterol diet: a new animal model for nonalcoholic fatty liver disease.Experimental animals · 2019Article
- The utility of apoptosis inhibitor of macrophages as a possible diagnostic marker in patients with Crohn's disease.BMC gastroenterology · 2017Article
- Association of apoptosis inhibitor of macrophage (AIM) expression with urinary protein and kidney dysfunction.Clinical and experimental nephrology · 2017Article
- Verification of B-lymphocyte activating factor's involvement in the exacerbation of insulin resistance as well as an autoimmune response in patients with nonalcoholic steatohepatitis and patients with HCV-related chronic liver disease.Diabetology & metabolic syndrome · 2017Article
- Impact of feline AIM on the susceptibility of cats to renal disease.Scientific reports · 2016Article
- MafB deficiency accelerates the development of obesity in mice.FEBS open bio · 2016Article
- Apoptosis inhibitor of macrophage protein enhances intraluminal debris clearance and ameliorates acute kidney injury in mice.Nature medicine · 2016Article
- Interaction of AIM with insulin-like growth factor-binding protein-4.International journal of molecular medicine · 2015Article
- Retinol-binding protein 4 and its potential roles in hypercholesterolemia revealed by proteomics.EXCLI journal · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is associated with various metabolic and cardiovascular diseases caused by chronic, low-grade inflammation that is initially observed in obese adipose tissue. In addition, many etiological studies in humans have shown a strong correlation between obesity and inflammatory autoimmune diseases. In this review, we focus on the involvement of apoptosis inhibitor of macrophage (AIM), a macrophage-derived blood protein, in both types of immune response. Through differential mechanisms, AIM thereby plays key roles in the pathogenesis of atherosclerosis, metabolic diseases, and obesity-associated autoimmune diseases. Thus, the regulation of blood AIM levels or AIM function has the potential to serve as a next-generation therapy against these inflammatory diseases brought about by modern lifestyle.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.